Clinical-stage biopharmaceutical company Anavex Life Sciences Corp (Nasdaq: AVXL) on Monday reported data showing that over three years of continuous treatment with blarcamesine demonstrated significantly reduced clinical decline in early Alzheimer's disease patients.

The ATTENTION-AD trial followed a 48-week double-blind clinical trial with an open-label extension to evaluate the safety and tolerability of blarcamesine. Blarcamesine-treated patients showed improved cognition and function over three years, as measured by ADAS-Cog13 and ADCS-ADL.

A delayed-start analysis demonstrated that early treatment initiation with blarcamesine resulted in greater stability of cognitive function compared to those who initiated treatment later. Blarcamesine exhibited a favourable safety profile with no treatment-related deaths.

These findings suggest that early treatment initiation with blarcamesine may have a significant positive impact on disease progression in early Alzheimer's disease.

Anavex focuses on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders.